Anti-Cancer Peptide Composition for Selective CD95 Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer therapies face challenges in achieving broad anti-cancer efficacy while minimizing toxicity to normal cells, as tumor-associated neutrophils can promote tumorigenesis and existing treatments lack specificity and genetic diversity in targeting cancer cells.
Innovation Solution
Utilizing peptides with specific amino acid sequences (SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5) that mimic the action of ELANE, a protein released by human PMNs, to cleave CD95 and induce apoptosis in cancer cells, thereby providing broad anti-cancer efficacy with limited toxicity to non-cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents are used to treat cancer, then tumor growth can be inhibited, but severe side effects occur including immunosuppression and damage to healthy tissues
Solution Approach 1:
The invention segments the therapeutic approach by using peptide-based drugs that specifically target cancer cells through their ability to bind to integrin receptors, separating the therapeutic action from healthy tissues. This segmentation allows selective delivery of cytotoxic effects only to malignant cells while sparing normal cells from damage.
Solution Approach 2:
The patent employs integrin-binding peptides as intermediaries that mediate the selective delivery of therapeutic effects to cancer cells. These peptides act as mediators that recognize and bind specifically to integrin receptors overexpressed on cancer cell surfaces, thereby directing the therapeutic action precisely to the target cells and avoiding healthy tissues.
2Reliability
If traditional chemotherapy is administered, then cancer cell proliferation is suppressed, but the treatment lacks selectivity and damages normal cells
Solution Approach 1:
The invention applies local quality by designing peptides with specific amino acid sequences that confer selective binding affinity for integrin receptors on cancer cells. This localized specificity ensures that the therapeutic effect is concentrated at the target site (cancer cells) while leaving other tissues unaffected, thereby achieving both suppression and selectivity simultaneously.
Solution Approach 2:
The patent utilizes parameter changes by modifying peptide sequences to optimize their binding affinity and specificity for integrin receptors. By adjusting parameters such as amino acid composition, length, and structural conformation, the peptides achieve enhanced selectivity for cancer cells while maintaining effective suppression of tumor growth.
3Reliability
If high doses of chemotherapy are used to improve treatment effectiveness, then tumor control improves, but toxicity to healthy tissues increases
Solution Approach 1:
The invention converts the harm of non-specific chemotherapy toxicity into benefit by using integrin-binding peptides that exploit the overexpression of integrin receptors on cancer cells. This selective targeting mechanism transforms the previously harmful non-specific cytotoxicity into a beneficial selective anti-cancer effect, achieving tumor control without damaging healthy tissues.
Solution Approach 2:
The patent employs self-service by designing peptides that autonomously target and bind to integrin receptors on cancer cells without requiring external guidance or complex delivery systems. The peptides inherently possess the ability to seek out and bind to their target receptors, enabling self-directed delivery of therapeutic effects precisely where needed.
Data Source
Figure 1A~1C
Figure 1D~1F
Figure 1G~1J
AI summary
Embodiments of the current invention provide a solution to the problems associated with balancing patient toxicity with broad efficacy of cancer therapy. In particular, embodiments are directed to anti-cancer peptides that demonstrate a broad anti-cancer efficacy with a limited toxicity to normal or non-cancer cells.